In an interview to CNBC-TV18, JR Vyas, CMD of Dishman Pharma said the company is likely to surpass their FY14 revenue guidance of Rs 1250-1300 crore by at least 5 percent.
Commenting on the company's China plant, he said the facility was doing extremely well and would reach breakeven by end of FY14.
Moreover, he confirmed that the company was in discussion to sell their SEZ land with Saudi Arabian firm call Bin laden firm, which is in JV with IL&FS.
Also read: 2013 in review: Pharma's year of quality woes
On the terms of sale for the SEZ land, Vyas said: "The terms given to potential client is Rs 300 crore upfront payment and Rs 200 when the initial park is established. The revenue share has yet to be finalised."
The deal is likely to be concluded in the next fiscal year, he said.
For entire interview, watch video.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
